PROteolysis TArgeting Chimera (PROTAC) Protein Degrader Cancer Therapeutics Market Global Report 2026

The proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market size has grown exponentially in recent years. It will grow from $1.48 billion in 2025 to $1.83 billion in 2026 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to rise of targeted cancer therapy demand, limitations of conventional small molecule inhibitors for undruggable proteins, advances in ubiquitin-proteasome system understanding, increasing investment in oncology drug discovery, growth of precision oncology biomarker development.

The proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market size is expected to see exponential growth in the next few years. It will grow to $4.24 billion in 2030 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to rising clinical trials for next generation protein degraders, expansion of applications into solid tumors beyond hematologic cancers, improved safety and pharmacokinetic optimization of degrader drugs, increasing regulatory approvals for novel degradation platforms, growing demand for personalized oncology therapeutics. Major trends in the forecast period include expansion of heterobifunctional protein degrader molecules targeting undruggable oncogenic proteins, development of molecular glue degraders as an alternative targeted protein degradation strategy, optimization of linker chemistry to improve cell permeability and oral bioavailability of degraders, diversification of e3 ligase ligand discovery to overcome resistance and expand target coverage, increasing use of combination regimens integrating protein degradation with existing oncology therapies.

The rising incidence of cancer is anticipated to drive the growth of the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market in the coming years. Cancer encompasses a group of disorders marked by the uncontrolled multiplication and progression of abnormal cells throughout the body. The growing burden of cancer cases is primarily attributed to an aging global population, as the likelihood of developing cancer increases with advancing age due to the gradual accumulation of genetic alterations. PROTAC protein degrader cancer therapeutics contribute to cancer treatment by precisely identifying and eliminating harmful proteins responsible for disease progression within cancer cells, helping to inhibit tumor development and address resistance to existing treatment approaches. For example, in May 2025, according to the National Cancer Institute, a U.S.-based government agency, approximately 2,041,910 new cancer cases were projected to be diagnosed in the United States, with around 618,120 cancer-related deaths expected. Hence, the increasing prevalence of cancer is contributing to the expansion of the PROTAC protein degrader cancer therapeutics market.

The growing investment in biotechnology and pharmaceutical research and development activities is expected to accelerate the growth of the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market. Biotechnology and pharmaceutical research and development spending refers to the financial resources dedicated to discovering, developing, and evaluating innovative drugs, biologics, and healthcare technologies aimed at enhancing patient outcomes. The increase in biotechnology and pharmaceutical research and development expenditure is being fueled by the rising need for advanced treatment options, as greater funding enables quicker innovation and the creation of more precise and effective therapeutic solutions. Proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics contribute to biotechnology and pharmaceutical research and development initiatives by encouraging investment in next-generation targeted therapies that enhance drug discovery processes and improve treatment performance. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a U.S.-based government statistical organization, research and development expenditures in the United States increased from $892 billion in 2022 to $940 billion in 2023, representing a growth of $48 billion. Therefore, the increasing expenditure on biotechnology and pharmaceutical research and development is supporting the growth of the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market.

Key companies operating in the PROTAC protein degrader cancer therapeutics market are focusing on developing innovative targeted protein degradation therapies, such as CDK2 PROTAC degraders, to improve treatment efficacy, overcome resistance mechanisms, and enable selective elimination of cancer-driving proteins. A CDK2 PROTAC degrader is a targeted therapeutic molecule designed to trigger the degradation of cyclin-dependent kinase 2 (CDK2), a key regulator of cell-cycle progression that is frequently associated with tumor growth and treatment resistance. For example, in October 2024, NiKang Therapeutics, a US-based biotechnology company, presented the discovery of NKT3964 at the EORTC-NCI-AACR Symposium 2024. NKT3964 is a first-in-class, highly potent, selective, and orally bioavailable CDK2 PROTAC degrader developed for cancer treatment. Preclinical studies demonstrated strong and selective CDK2 degradation, significant antitumor activity across multiple cancer models, and favorable pharmacokinetic properties, highlighting its potential as a next-generation targeted protein degradation therapy for oncology applications.

Major companies operating in the proteolysis targeting chimera (protac) protein degrader cancer therapeutics market report are Bayer AG, AstraZeneca PLC, Bristol Myers Squibb Company, BeiGene Ltd., SK Life Science Labs, PeptiDream Inc., Kymera Therapeutics Inc., Arvinas Inc., Nurix Therapeutics Inc., Monte Rosa Therapeutics Inc., Ascentage Pharma Group International, Cullgen Inc., C4 Therapeutics Inc., Ambagon Therapeutics Inc., Kintor Pharmaceutical Limited, Seed Therapeutics Inc., BioTheryX Inc., FIMECS Inc., Beactica Therapeutics AB, Captor Therapeutics S.A., Alivexis Inc., Gluetacs Therapeutics Inc., Roche Holding AG, Merck KGaA, Novartis AG, GlaxoSmithKline PLC, Sanofi SA.

North America was the dominating region in the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the proteolysis targeting chimera (PROTAC) protein degrader cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.